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Methyleugenol, or 4-allyl-1,2-dimethoxy-
benzene, occurs naturally in clove oil, nutmeg,
anise, allspice, cinnamon bark, walnuts, and
several exotic herbs and spices. Either synthe-
sized or of natural origin, methyleugenol is in
common use as a flavoring agent in candy,
cookies such as gingersnaps, ice cream, pies
such as pumpkin pie, puddings, cola soft
drinks, bubble gum, French toast, eggnog
topped with nutmeg, patés and terrines, tomato
ketchup and relish, sweet chili sauce, apple but-
ter, chutney, anise biscotti, mincemeat, and
gingerbread (Burdock 1995; Leung 1980).
Methyleugenol is also used as a fragrance in
some perfumes and toiletries at concentrations
of 0.002–0.3%. U.S. annual production of syn-
thesized methyleugenol is about 25,000
pounds (SRI International 1990).
Because of its widespread use and struc-
tural resemblance to the known carcinogens
safrole, isosafrole, and estragole, methyleugenol
was nominated for toxicologic characterization
and testing by the National Toxicology
Program (NTP) (Miller et al. 1983; NTP
1998). In these 2-year gavage studies, signiﬁ-
cant dose-related increases in neoplastic lesions
of the liver were found in both male and
female F344/N rats and B6C3F1 mice. In
addition, increases of kidney neoplasms, malig-
nant mesothelioma, mammary gland fibro-
adenoma, and subcutaneous fibroma and
ﬁbrosarcoma occurred in male rats, and neuro-
endocrine tumors of the glandular stomach
occurred in male mice and in male and female
rats. Also, methyleugenol is shown to possess
cytotoxicity and genotoxicity in rat hepatocytes
(Burkey et al. 2000). These findings consti-
tuted “clear evidence of carcinogenic activity,”
the highest category of evidence used by the
NTP for animal bioassays (NTP 1998).
The highest concentration of methyl-
eugenol found among food products sub-
jected to preliminary semiquantitative analyses
by the National Center for Environmental
Health of the Centers for Disease Control and
Prevention (CDC) was approximately 3.3 µg/g
methyleugenol in one brand of gingersnaps.
Lower concentrations were found (in decreas-
ing order) in other brands of gingersnaps, cin-
namon-flavored oatmeal, vinaigrette salad
dressing, cinnamon-flavored mints, a “red”
brand of chewing gum, cake doughnuts, and
cola beverages. The analytical methods used
for the food have not been validated for accu-
racy, reproducibility, or detection limits. In 20
other brands of gingersnaps and other cookies,
doughnuts, colas, and foods with cinnamon,
nutmeg, or ginger flavoring, methyleugenol
either was not detected or was found at con-
centrations < 0.05 µg/g. Methyleugenol has
also been measured in tobacco from U.S.
cigarettes (0.003–0.86 µg/g) and at higher
concentrations in flavored bidi cigarettes
(0.49–61 µg/g) (Stanﬁll et al. 2003).
In mice and rats, methyleugenol is metab-
olized very rapidly, and the metabolites are
found in urine within hours (NTP 1998).
Metabolism of the compound in humans has
not previously been studied. To the best of
our knowledge, no previous data exist on the
levels of methyleugenol or its metabolites in
urine of the U.S. general population, and only
one recently published study exists on blood
levels of methyleugenol (Barr et al. 2000).
The purpose of this collaborative study
was to determine the levels of methyleugenol
in human blood at certain times before and
after eating a common commercial food
product, gingersnap cookies, known to con-
tain the compound.
Materials and Methods
Study subjects. Twenty adults living in the
Raleigh–Durham area of North Carolina 
volunteered for the study in response to an
announcement that included a nominal pay-
ment in return for time spent for the experi-
ment. None were afﬁliated with the National
Institute of Environmental Health Sciences
(NIEHS). The study protocol, including
informed consent procedure, was approved
by the appropriate institutional review boards
for the protection of human subjects at the
National Institutes of Health. 
Volunteers were screened on the basis of a
standard occupational/environmental medical
history from Duke Medical Center (Durham,
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Under a mandate from the U.S. Congress, the National Toxicology Program (NTP) of the U.S.
Department of Health and Human Services conducts animal bioassays for carcinogenicity of
potentially toxic chemicals to which the U.S. population might be exposed. Methyleugenol, a nat-
ural as well as synthesized substance, was nominated for study because it is structurally similar to
safrole, a known animal carcinogen. Methyleugenol was found to be a very potent multisite car-
cinogen in male and female F344/N rats and B6C3F1 mice at all doses tested in 2-year NTP
bioassays using gavage dosing. For this reason, human toxicokinetic studies were added to the tra-
ditional NTP protocol. A commercial brand of gingersnaps was found by chemists at the Centers
for Disease Control and Prevention to contain a relatively high concentration of methyleugenol.
After thorough scientiﬁc and clinical review, and approval by a National Institutes of Health insti-
tutional review board for the protection of human subjects, a study was conducted with nine
healthy adult male and female human volunteers. The volunteers were given 12 gingersnaps for
breakfast. Blood was drawn immediately before the meal and at 15, 30, 60, and 120 min after-
ward. The mean ± SD fasting level of methyleugenol in serum was 16.2 ± 4.0 pg/g wet weight.
Peak blood levels were found at 15 min (mean ± SD, 53.9 ± 7.3 pg/g wet weight), followed by a
rapid decline; the half-life of elimination was about 90 min. The peak levels were within the range
of methyleugenol blood levels in the U.S. population, as measured concurrently in a subset of
nonfasting participants in the Third National Health and Nutrition Examination Survey
(NHANES III). Key words: 4-allyl-1,2-dimethoxybenzene, carcinogen, dose, food, human, inges-
tion, kinetics, methyleugenol, serum levels, urine. Environ Health Perspect 112:678–680 (2004).
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1966). Pregnant women and persons with a
diagnosed illness were excluded, as were per-
sons taking any medicine for treatment of
illness, with the exception of aspirin, aceta-
minophen, allergy medications, and oral con-
traceptives. Five male and four female
volunteers met the inclusion criteria and agreed
to participate.
Feeding study. The volunteers were
instructed to fast from midnight until report-
ing to the NIEHS health station for the study
at 0730 hr. Each person arrived with a com-
pleted food survey listing all foods consumed
after dinner the previous evening. There were
no dietary restrictions. Height, weight, tem-
perature, and blood pressure were recorded,
followed by an initial blood draw.
Volunteers were then served a breakfast
known to contain methyleugenol, consisting
of the brand of gingersnaps found on initial
analysis to contain approximately 3.3 µg
methyleugenol per gram, or 18 µg/cookie.
The gingersnaps were purchased locally from
a large supermarket chain. Orange juice was
provided as a beverage. Each subject’s meal
consisted of 12 gingersnaps, containing
approximately 216 µg methyleugenol. This
was the largest practical dosing felt to be rep-
resentative of a moderate dietary intake in
average adult volunteers ingesting commercial
food containing methyleugenol.
Specimen collection. Blood was collected at
15, 30, 60, and 120 min after the meal of gin-
gersnaps. The times were based on a model of
the anticipated rates of absorption, distribu-
tion, and elimination of methyleugenol in
humans developed before contracting this
study (Blumenthal G, personal communica-
tion). Blood samples were centrifuged and the
cell layer discarded. Serum for future study
were frozen after collection and sent to CDC
frozen on dry ice.
Methyleugenol analysis. Methyleugenol
analyses were performed on a 4-mL aliquot of
serum spiked with a 13C3-labeled methyl-
eugenol internal standard (Barr et al. 2000).
The serum was ﬁltered to 0.2 µL and denatured
with 50% formic acid, and then aspirated
through a C18 solid-phase extraction cartridge.
The cartridge was washed with water and
eluted with methylene chloride. The eluate was
cleaned up on a silica cartridge with 1 g anhy-
drous sodium sulfate and then concentrated to
10 µL after addition of a keeper solvent and
recovery standard. A 2-µL sample was analyzed
by gas chromatography–high-resolution mass
spectrometry in the single-ion monitoring
mode at 10,000 resolution. Two ions were
monitored for methyleugenol (m/z 178.0994,
which is M+, and m/z 163.0759, which is
M-CH3
+) and one ion each for the labeled
internal standard (m/z 181.1094) and recovery
standard [m/z 164.0473; 3´,4´-(methylene-
dioxy)-acetophenone]. The 178.0994 ion was
used for quantiﬁcation and the 163.0759 for
confirmation. The limit of detection of the
method was 3.1 pg/g, and the relative SD
(RSD) ranged from 8.9% to 21%. The higher
RSDs were seen at the low concentration end
of the linear range. Extensive checks for quality
control and quality assurance were incorpo-
rated into the method (Barr et al 2000).
Results
Subjects. Age, sex, height, and weight of sub-
jects are shown in Table 1. All were healthy
residents of North Carolina living in or near
Durham, Cary, or Research Triangle Park.
Serum levels. Measured levels of methyl-
eugenol as picograms per gram (parts per
trillion) in serum are presented in Table 2
and as nanograms per gram (parts per bil-
lion), lipid basis, in Table 3. The time course
of median wet weight serum levels is repre-
sented graphically in Figure 1. The median
fasting level of methyleugenol in serum was
13 pg/g wet weight (range, < 3.1–37 pg/g).
The median serum level at 15 min peaked at
54 pg/g wet weight (range, 25–100 pg/g).
The median level declined to 40 pg/g (range,
26–99 pg/g) at 30 min, to 29 pg/g (range,
13–94 pg/g) at 1 hr, and to 20 pg/g (range,
15–61 pg/g) at 2 hr.
Discussion
Results for methyleugenol levels in serum
from the human clinical study, in which sub-
jects ate gingersnaps, were consistent with
expectations (based on elimination rates in
male and female F344/N rats and B6C3F1
mice) that methyleugenol blood levels in
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Table 1. Methyleugenol subject proﬁles.
Subject  Sex Age (years) Weight (lbs) Height (inches)
A Male 20 175 71
C Female 20 109 63
D Female 47 116 63
E Male 37 176 74
F Female 27 235 68
H Male 50 189 70
I Male 21 164 74
J Female 36 133 63
K Male 37 146 70
Table 2. Serum levels [pg/g (ppt) wet weight] of methyleugenol in nine human volunteers at ﬁve time points before and after dosing. 
Subject
Time A C D E F H I J K Mean Median
Prefeed 16 30 25 37a 9.5 13 5.2 8.8 NDb,c 16.2 13
15 min 58 100a 60 43 40 69 54 25b 36 53.9 54
30 min 38 99a 42 26 26b 40 40 47 28 42.9 40
1 hr 46 94a 41 23 13b 23 28 29 36 37.0 29
2 hr 20 61a 37 15b 20 20 15 19 20 25.2 20
ND, not detected.
aMaximum value for row. bMinimum value for row. cHalf the limit of detection (1.55 pg/g) was used as the serum value in calculating the mean. 
Table 3. Serum levels [ng/g (ppb) lipid basis] of methyleugenol in nine human volunteers at ﬁve time points before and after dosing. 
Subject
Time A C D E F H I J K Mean Median
Prefeed 2.5 5.2 4 5.7a  1.1 2.2 1.3 2 NDb,c  2.7 2.2
15 min 9.3 17a  9.7 6.6 4.4b 12 13 5.4 5.4 9.2 9.3
30 min 6.1 17a  6.9 4.0 3.2b 6.8 9.6 10 4.7 7.6 6.8
1 hr 7.4 16a  6.3 3.5 1.5b 4.2 6.9 6.5 5.7 6.4 6.3
2 hr 3.4 10a  5.6 2.2b 2.3 3.5 2.8 4.3 3.7 4.2 3.5
ND, not detected. 
aMaximum value for row. bMinimum value for row. cIn calculation of the mean, 0.3 ng/g was used as the lipid-based level. Article | Schecter et al.
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human adults would peak rapidly after a meal
and have a half-life of elimination of about
90 min. The mean ± SD methyleugenol
plasma concentrations (wet weight) at the
lowest dose (37 mg/kg) 15 min after gavage
exposure were 573 ± 228 ng/g (ppb) for male
rats and 652 ng/g (two samples, no SD) for
female rats. In mice, the mean ± SD  concen-
trations in plasma (wet weight) for the lowest
exposure group (37 mg/kg) 10 min after expo-
sure were 417 ± 128 ng/g for males and 681 ±
50 ng/g for females (NTP 1998). At these
doses, the increased liver cancer risks were
17.5%, 17.1%, 34%, and 52.2% in male and
female rats and male and female mice, respec-
tively. The human plasma concentrations were
roughly 10,000 times smaller, with an average
concentration of 0.0539 ± 0.0083 ng/g. The
average weight for humans was 68.3 kg yield-
ing a dosage of 3.16 µg/kg, which is approxi-
mately 10,000 times smaller than the dose
given the rodents.
For humans, the estimated half-life of
methyleugenol was approximately 100 min
(95% conﬁdence interval, 1–6 hr).
In a concurrent study of 213 nonfasting
subjects in the third National Health and
Nutrition Examination Survey (NHANES III,
1988–1994), the range of serum levels of
methyleugenol was < 3.1–390 pg/g, with a
median of 16 pg/g (National Center for Health
Statistics 1994). In 16 subjects, serum levels of
methyleugenol exceeded 54 pg/g, the median
peak level observed in the clinical study. Four
NHANES subjects had serum levels exceeding
100 pg/g, the highest peak level measured in
this clinical experiment. The maximum con-
centration found, 390 pg/g, is nearly four times
the highest concentration found in this clinical
study but still nearly 2,000 times less than peak
levels observed at the lowest dose used in the
NTP rodent studies (Barr et al. 2000).
Methyleugenol has been proposed to be
metabolized extensively by various cytochrome
P450 isozymes, with metabolism rates by
human liver microsomal preparations varying
more than 37-fold (Gardner et al. 1997).
Therefore, this broad range of concentrations
found in the NHANES sample (from below
the limit of detection to 300 pg/g) may repre-
sent a combination of differences in metabolic
rates, time since last meal, and food consumed
at last meal.
The ﬁnding of methyleugenol in the blood
of the general U.S. population at levels higher
than the peak levels obtained in the clinical
study was unexpected, and the signiﬁcance of
these levels with respect to health conse-
quences remains to be determined. The infor-
mation from these studies has been shared
with the U.S. Food and Drug Administration.
The reasons for an elevated level in a substan-
tial number of adults in the general U.S.
population require further investigation, as
does the risk of cancer and other health
effects associated with background levels of
exposure to methyleugenol.
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